Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 45

1.

Persistence of Mycobacterium tuberculosis in macrophages and mice requires the glyoxylate shunt enzyme isocitrate lyase.

McKinney JD, Höner zu Bentrup K, Muñoz-Elías EJ, Miczak A, Chen B, Chan WT, Swenson D, Sacchettini JC, Jacobs WR Jr, Russell DG.

Nature. 2000 Aug 17;406(6797):735-8.

PMID:
10963599
2.

Molecular mechanisms regulating persistent Mycobacterium tuberculosis infection.

Zahrt TC.

Microbes Infect. 2003 Feb;5(2):159-67. Review.

PMID:
12650774
3.

Isocitrate lyase: a potential target for anti-tubercular drugs.

Sharma R, Das O, Damle SG, Sharma AK.

Recent Pat Inflamm Allergy Drug Discov. 2013 May;7(2):114-23. Review.

PMID:
23506018
4.

[Protective immunity against Mycobacterium tuberculosis].

Kawamura I.

Kekkaku. 2010 Jun;85(6):539-46. Review. Japanese.

PMID:
20662250
5.

Mycobacteria and macrophage activation.

van Furth R.

Res Microbiol. 1990 Feb;141(2):256-61. Review.

PMID:
2111929
6.

Defining the requirements for immunological control of mycobacterial infections.

Murray PJ.

Trends Microbiol. 1999 Sep;7(9):366-72. Review.

PMID:
10470045
7.

Immunopathogenesis of Mycobacterium avium infection.

Cooper AM, Appelberg R, Orme IM.

Front Biosci. 1998 Aug 5;3:e141-8. Review.

8.

Potential inhibitors for isocitrate lyase of Mycobacterium tuberculosis and non-M. tuberculosis: a summary.

Lee YV, Wahab HA, Choong YS.

Biomed Res Int. 2015;2015:895453. doi: 10.1155/2015/895453. Epub 2015 Jan 8. Review.

9.

PPE2 protein of Mycobacterium tuberculosis may inhibit nitric oxide in activated macrophages.

Bhat KH, Das A, Srikantam A, Mukhopadhyay S.

Ann N Y Acad Sci. 2013 Apr;1283:97-101. doi: 10.1111/nyas.12070. Epub 2013 Feb 28. Review.

PMID:
23448669
10.

Roles of lipoarabinomannan in the pathogenesis of tuberculosis.

Strohmeier GR, Fenton MJ.

Microbes Infect. 1999 Jul;1(9):709-17. Review.

PMID:
10611748
11.

A delicate dance: host response to mycobacteria.

Huynh KK, Joshi SA, Brown EJ.

Curr Opin Immunol. 2011 Aug;23(4):464-72. doi: 10.1016/j.coi.2011.06.002. Epub 2011 Jul 3. Review.

PMID:
21726990
12.

Macrophages and Mycobacterium tuberculosis: the key to pathogenesis.

Rook GA.

Immunol Ser. 1994;60:249-61. Review. No abstract available.

PMID:
8251572
13.

Mycobacterium tuberculosis modulators of the macrophage's cellular events.

Poirier V, Av-Gay Y.

Microbes Infect. 2012 Nov;14(13):1211-9. doi: 10.1016/j.micinf.2012.07.001. Epub 2012 Jul 25. Review.

PMID:
22841679
14.

[Mycobacterium tuberculosis--intracellular pathogen. Relationship between mycobacteria and the host].

Vrba A, Kwiatkowska S.

Pol Merkur Lekarski. 2009 Dec;27(162):508-13. Review. Polish.

PMID:
20120719
15.

Experimental models used to study human tuberculosis.

O'Toole R.

Adv Appl Microbiol. 2010;71:75-89. doi: 10.1016/S0065-2164(10)71003-0. Epub 2010 Feb 20. Review.

PMID:
20378051
16.

[Macrophage activity in anti-Mycobacterium immunity. II. Direct contact of Mycobacterium tuberculosis with the macrophage].

Lipińska R.

Pneumonol Pol. 1982 Oct;50(10):535-9. Review. Polish. No abstract available.

PMID:
6820496
17.

Dying to live: how the death modality of the infected macrophage affects immunity to tuberculosis.

Divangahi M, Behar SM, Remold H.

Adv Exp Med Biol. 2013;783:103-20. doi: 10.1007/978-1-4614-6111-1_6. Review.

18.

Macrophage takeover and the host-bacilli interplay during tuberculosis.

Hussain Bhat K, Mukhopadhyay S.

Future Microbiol. 2015;10(5):853-72. doi: 10.2217/fmb.15.11. Review.

PMID:
26000654
19.

Advances in mycobacterial isocitrate lyase targeting and inhibitors.

Krátký M, Vinšová J.

Curr Med Chem. 2012;19(36):6126-37. Review.

PMID:
23092127
20.

Virulence factors of the Mycobacterium tuberculosis complex.

Forrellad MA, Klepp LI, Gioffré A, Sabio y García J, Morbidoni HR, de la Paz Santangelo M, Cataldi AA, Bigi F.

Virulence. 2013 Jan 1;4(1):3-66. doi: 10.4161/viru.22329. Epub 2012 Oct 17. Review.

Items per page

Supplemental Content

Write to the Help Desk